Diseases & Conditions
Grants & Contracts
News & Events
June 10, 2022
A new comparison study in PNAS from NIAID intramural scientists clearly shows that for SARS-CoV-2, nasal vaccination – particularly in two doses – has clear advantages over muscular delivery in laboratory mice.
June 07, 2022
NIAID investigators recently published initial results from a study seeking to characterize and better understand persistent symptoms some people experience after having COVID. These persistent symptoms, often referred to as “long COVID,” can sometimes be debilitating, and their cause is currently unknown. This single-site study is part of a larger research effort across multiple institutes at NIH and NIH-funded institutions to understand, prevent, and treat long-term health effects related to COVID-19.
May 19, 2022
The national EV-D68 pilot study is part of PREMISE, the Pandemic Response Repository through Microbial and Immune Surveillance and Epidemiology. PREMISE is an initiative from NIAID’S Vaccine Research Center (VRC) that began in early 2021.
May 18, 2022
Today marks the 25th anniversary of the first HIV Vaccine Awareness Day. Although tremendous progress has been made over the past several decades in HIV treatment and prevention, the development of a safe, effective, and durably protective vaccine to prevent HIV infection has, unfortunately, remained elusive. On this commemorative day, NIAID acknowledges the disappointments of the past while optimistically looking ahead to what’s next in HIV vaccine development.
May 11, 2022
NIAID researchers designed a ferritin nanoparticle flu vaccine and tested it in people with and without immunological experience of the flu virus that caused the 1957 pandemic. The experimental vaccine prompted immune responses that suggested this kind of vaccine could provide long-lasting protection against many flu subtypes.
March 31, 2022
When the next SARS-CoV-2 variant of concern emerges in the world, NIAID will call on SAVE – its version of The Avengers – to quickly react and protect people. SAVE (SARS-CoV-2 Assessment of Viral Evolution) members assess whether mutations in variants can affect virus transmission, severity and immunity; test vaccines and therapeutics; and guide responses.
March 01, 2022
As the 2022 virtual Conference on Retroviruses and Opportunistic Infections came to a close, NIAID's Dr. Carl Dieffenbach joined HIV.gov for a video conversation on February 24 to discuss important findings on cancer prevention in people with HIV, research on HIV and aging, and the future of HIV prevention and treatment. Dr. Dieffenbach is the Director of the NIAID Division of AIDS.
February 18, 2022
In an HIV.gov video conversation on February 16, NIAID's Dr. Carl Dieffenbach discussed some of the pivotal HIV research advances presented this week at the 2022 virtual Conference on Retroviruses and Opportunistic Infections (CROI 2022). Dr. Dieffenbach, who directs the Division of AIDS, covered developments in HIV cure, treatment and prevention research. Watch the conversation and read summaries of the study findings he discussed.
February 18, 2022
A comprehensive analysis evaluating immune responses in children with SARS-CoV-2 infection and in those with a rare post-infection inflammatory syndrome called MIS-C has revealed distinct immunopathological signatures associated with each condition.
February 04, 2022
Add Staphylococcus epidermidis to the list of common human bacteria undergoing an image change: From bad reputation of “disease causing” to something helpful – and likely interesting to probiotic users.
January 28, 2022
January 30, 2022, marks the third World Neglected Tropical Diseases (NTDs) Day, presenting an opportunity to reflect both on the continuing burden imposed by these diseases and the significant progress made to curtail them. NTDs comprise viral, bacterial, fungal and parasitic diseases that, despite their various causes, have in common their substantial health, social and economic impacts, especially on marginalized populations living in tropical and subtropical countries.
January 26, 2022
NIAID preclinical study shows drug FPS-ZM1 could limit COVID-19 lung damage.
December 10, 2021
A new study in mice from NIAID scientists now shows that toxins from Staphylococcus aureus alarm the immune system hours earlier than previously known.
December 08, 2021
A pediatric clinical trial is being planned for a single vaccine that would protect against SARS-CoV-2, the virus that causes COVID-19, and human parainfluenza virus type 3.
November 24, 2021
Antimicrobials such as antibiotics, antivirals, and antifungal drugs are crucial tools in the fight against disease-causing microbes. However, resistance of microbes to these life-saving medicines is a growing global public health dilemma. In fact, the Centers for Disease Control and Prevention (CDC) reports that more than 2.8 million infections and over 35,000 deaths are caused by antibiotic-resistant pathogens in the US annually.
November 24, 2021
A new study from NIAID's Intramural research program provides an update on research into using a probiotic to treat bacterial gut infections.
November 17, 2021
NIAID launched the Centers for Research in Emerging Infectious Diseases Network (CREID Network) in August 2020. One key component of the CREID Network is the Pilot Research Program, which provides financial support and mentorship opportunities to early-career researchers. The program focuses on training the next generation of emerging infectious disease researchers to build expertise and research capacity around the world.
November 04, 2021
The National Institutes of Health has awarded approximately $16 million to support implementation science research to advance the goals of Ending the HIV Epidemic in the U.S. (EHE), which aims to reduce new HIV infections in the United States by at least 90% by 2030.
October 29, 2021
Plasmodium falciparum, the parasite that causes malaria, creates a significant burden of morbidity and mortality around the world. In pregnant women, P falciparum- infected red blood cells (iRBCs) collect in vascular spaces of the placenta by binding to chondroitin sulfate A (CSA). This sequestration of iRBCs can result in inflammatory responses, which can lead to many adverse pregnancy outcomes such as severe maternal anemia, fetal growth retardation, premature delivery, maternal and/or perinatal mortality.
October 28, 2021
NIAID-supported research can help fuel further discovery when data are shared quickly in discoverable repositories, following community standards for metadata. Data sharing enables more rapid and open scrutiny of research results and outcomes and allows data across studies to be easily combined and analyzed.
October 22, 2021
The NIAID-NCATS collaboration allowed scientists to screen 3,833 FDA-approved drugs and small molecules. Only one of these, Rottlerin, consistently inhibited induced cell death and virus replication by La Crosse virus in human and mouse neuronal cell lines. Rottlerin is a natural compound isolated from the Kamala tree.
September 08, 2021
The Office of NIH History and Stetten Museum this month is honoring one of the forerunners to Rocky Mountain Laboratories – the Schoolhouse Lab at Canyon Creek, just west of Hamilton, Montana – where 100 years ago scientists worked to develop a vaccine against Rocky Mountain spotted fever.
September 01, 2021
Antiretroviral therapy of pregnant women and antiretroviral treatment of infants have greatly reduced the rate of mother-to-child HIV transmission, also referred to as vertical transmission. Nevertheless, although these improved rates have occurred in some countries, vertical transmission rates remain relatively high in others. This may be due to multiple factors, including access to testing, care and antiretroviral therapy, adherence to antiretroviral therapy during pregnancy and breastfeeding, and potential HIV drug resistance.
August 27, 2021
Mice infected during pregnancy generated an immune response in the gut that protected the mother and imprinted that protective response in the developing offspring -- but the response also could make offspring more susceptible to inflammation.
August 23, 2021
For 30 years a group at NIAID’s Rocky Mountain Laboratories worked to define the structure of an infectious prion protein. Last winter, during a pandemic and working 2,000 miles from collaborators, they finished. Or is this a new beginning?